⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNYSE

HAE

Haemonetics Corporation

Healthcare · Medical Devices

103.16USD

+0.3200 (+0.31%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Loading security description…
A first visit to a security takes a few seconds.

Haemonetics Corporation

Ticker HAE · NYSE
Healthcare »Research »
Classification Medical Devices

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

1)

Price Chart

GP »

Price

 

 

1M6MYTD1Y5Y
Close
Px/Chg 1D (USD)103.16 / +0.31%
52 Wk H (08/21/26)108.80
52 Wk L (09/25/25)47.67
YTD Change/%22.69 / 28.3%
Mkt Cap (USD)4.7B
Shrs Out/Float45.5M / 44.9M
SI/% of Float2.8M / 7.1%
Days to Cover3.7
2)

Estimates

EE »
Next Report11/05/26
P/E49.84
Est P/E 03/202717.97
T12M EPS (USD)2.07
Est EPS5.74
Est PEG1.63
Analyst Target$108.40
3)

Dividend

DVD »
Ind Gross Yield—
Ind Ann Dvd (USD)—
5Y Avg Yield—
Cash—
Payout Ratio0.0%
Ex-Dvd Date—
4)

Total Return

COMP »
1M+17.08%
3M+30.66%
6M+63.63%
1Y+90.09%
3Y+16.23%
5Y+56.63%
52W vs SPX+91.62% / +17.48%
Beta0.54
5)

Trading

HP »
Day Range100.57 - 103.16
Prev Close102.84
Volume0.6M
Avg Volume0.8M
50d Avg88.24
200d Avg72.83
Employees3,009

Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.